Breaking News Instant updates and real-time market news.

2020-05-01 10:33:13 PCG PG&E $10.02 / -0.67 (-6.27%) 10:33 05/01/20 05/01 10:33 05/01/20 10:33	PG&E says on track for court confirmation of plan of reorganization by June 30 Earlier, PG&E Corporation said it continues to make substantial progress in reorganization cases and remains on track for bankruptcy court confirmation of its plan of reorganization by June 30, allowing the company to participate in California's new go-forward wildfire fund. PG&E has previously reached settlements with all major groups of wildfire victims to be implemented pursuant to its Plan, valued at approximately $25.5B at plan value. Voting by eligible parties is now underway, and ballot counting is expected to be complete by the third week of May, the company said.
PCG PG&E $10.02 / -0.67 (-6.27%) 04/07/20 Mizuho PG&E price target lowered to $12.50 from $15.50 at Mizuho 04/06/20 Mizuho Mizuho expects PG&E share offering to price at 'significant premium' 04/02/20 Citi Citi sees stock rally for PG&E, boosts price target to $17 03/31/20 Morgan Stanley PG&E price target lowered to $10 from $16 at Morgan Stanley

2020-05-01 10:33:13

PCG

PG&E

$10.02 / -0.67 (-6.27%)

10:33

05/01/20

05/01

10:33

05/01/20

10:33

PG&E says on track for court confirmation of plan of reorganization by June 30

Earlier, PG&E Corporation said it continues to make substantial progress in reorganization cases and remains on track for bankruptcy court confirmation of its plan of reorganization by June 30, allowing the company to participate in California's new go-forward wildfire fund. PG&E has previously reached settlements with all major groups of wildfire victims to be implemented pursuant to its Plan, valued at approximately $25.5B at plan value. Voting by eligible parties is now underway, and ballot counting is expected to be complete by the third week of May, the company said.

PCG PG&E

$10.02 / -0.67 (-6.27%)

04/07/20 Mizuho: PG&E price target lowered to $12.50 from $15.50 at Mizuho

04/06/20 Mizuho: Mizuho expects PG&E share offering to price at 'significant premium'

04/02/20 Citi: Citi sees stock rally for PG&E, boosts price target to $17

03/31/20 Morgan Stanley: PG&E price target lowered to $10 from $16 at Morgan Stanley

TODAY'S FREE FLY STORIES

Upgrade	Itron upgraded to Buy from Hold at Argus » 07:19 03/03/21 03/03 07:19 03/03/21 07:19 ITRI Itron $117.75 / -0.06 (-0.05%) Argus analyst John Eade… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events ITRI Itron $117.75 / -0.06 (-0.05%) 02/17/21 Bsquare, Itron extend pact over industrial IoT innovation 01/19/21 Itron and Versant Power collaborate to modernize electricity grid in Maine 10/05/20 ON Semiconductor appoints Itron CEO Thomas Deitrich to board 10/05/20 Itron, Con Ed confirm, NYS affirmed its consent approval for Itron ERT module ITRI Itron $117.75 / -0.06 (-0.05%) 02/25/21 Oppenheimer Itron price target raised to $127 from $75 at Oppenheimer 01/08/21 Raymond James Itron downgraded to Outperform from Strong Buy at Raymond James 01/08/21 Raymond James Itron downgraded to Outperform from Strong Buy at Raymond James 10/15/20 Stephens Itron resumed with an Overweight at Stephens ITRI Itron $117.75 / -0.06 (-0.05%) 02/24/21 Itron sees FY21 EPS $2.15-$2.55, consensus $2.26 02/24/21 Itron reports Q4 EPS 65c, consensus 30c 11/02/20 Itron reports Q3 EPS 61c, consensus 25c 03/08/21 Itron
Initiation	BlackRock TCP Capital resumed with an Outperform at JMP Securities » 07:19 03/03/21 03/03 07:19 03/03/21 07:19 TCPC BlackRock TCP Capital / + JMP Securities analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research Earnings TCPC BlackRock TCP Capital / + 02/26/21 Raymond James BlackRock TCP Capital upgraded to Outperform from Market Perform at Raymond James 02/26/21 Raymond James BlackRock TCP upgraded to Outperform from Market Perform at Raymond James 06/24/20 Raymond James TCP Capital downgraded to Market Perform from Outperform at Raymond James 06/24/20 Raymond James TCP Capital downgraded to Market Perform from Outperform at Raymond James TCPC BlackRock TCP Capital / + 11/02/20 BlackRock TCP Capital reports Q3 NII 35c, consensus 32c
Hot Stocks	Kamada closes aquisition of FDA-licensed plasma collection center » 07:19 03/03/21 03/03 07:19 03/03/21 07:19 KMDA Kamada $6.10 / -0.1 (-1.61%) Kamada updated that it… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Options KMDA Kamada $6.10 / -0.1 (-1.61%) 02/24/21 Kamada files 2020 annual report 02/10/21 Kamada to continue to focus on expanding existing growth drivers 02/01/21 Kamada acquires plasma collection center from Blood and Plasma Research 01/13/21 Kamada enters two agreements for distribution of three biosimilar products KMDA Kamada $6.10 / -0.1 (-1.61%) 08/14/20 Chardan Kamada price target raised to $11 from $7 at Chardan KMDA Kamada $6.10 / -0.1 (-1.61%) 02/10/21 Kamada reports Q4 EPS 4c, consensus 7c 11/11/20 Kamada reaffirms FY20 revenue view $132M-$137M, consensus $134.75M 11/11/20 Kamada reports Q3 EPS 15c, consensus 6c KMDA Kamada $6.10 / -0.1 (-1.61%) 09/16/20 Eight new option listings and one option delisting on September 16th
Upgrade	Roku upgraded to Overweight at KeyBanc on video monetization » 07:18 03/03/21 03/03 07:18 03/03/21 07:18 ROKU Roku $389.13 / -31.09 (-7.40%) , NLSN Nielsen $24.83 / +1.74 (+7.54%) As previously reported,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Options ROKU NLSN ROKU Roku $389.13 / -31.09 (-7.40%) 03/01/21 Roku to acquire Nielsen's video advertising business 02/18/21 Roku CEO says FY21 revenue growth to fall below levels of Q1 and Q2 02/18/21 Roku reports Q4 Active accounts 51.2M vs. 36.9M last year 01/21/21 Cinedigm launches All3Media's streaming channel SO... REAL App on Roku NLSN Nielsen $24.83 / +1.74 (+7.54%) 03/01/21 Roku to acquire Nielsen's video advertising business 02/25/21 Twitter exploring 'super follows,' users able to subscribe for exclusive content 02/16/21 Elliott buys Evergy, exits eBay in Q4 01/12/21 Nielsen begins tracking premium theatrical films distributed via streaming ROKU NLSN ROKU Roku $389.13 / -31.09 (-7.40%) 04:40 Today KeyBanc Roku upgraded to Overweight from Sector Weight at KeyBanc 02/22/21 Needham Roku price target raised to $550 from $400 at Needham 02/19/21 Truist Roku price target raised to $480 from $390 at Truist 02/19/21 JPMorgan Roku price target raised to $525 from $475 at JPMorgan NLSN Nielsen $24.83 / +1.74 (+7.54%) 03/02/21 Truist Nielsen price target raised to $26 from $20 at Truist 03/01/21 Truist Nielsen price target raised to $26 from $20 at Truist 01/28/21 Citi Nielsen price target raised to $27 from $22 at Citi 11/03/20 Deutsche Bank Nielsen price target lowered to $18 from $22 at Deutsche Bank ROKU NLSN ROKU Roku $389.13 / -31.09 (-7.40%) 02/18/21 Roku sees Q1 revenue $478M-$493M, consensus $462.97M 02/18/21 Roku reports Q4 EPS 49c, consensus (5c) 02/18/21 Notable companies reporting after market close 11/05/20 Roku reports Q3 EPS 9c, consensus (40c) NLSN Nielsen $24.83 / +1.74 (+7.54%) 02/25/21 Nielsen sees FY21 adjusted EPS $1.43-$1.54, consensus $1.66 02/25/21 Nielsen reports Q4 adjusted EPS 53c, consensus 46c 02/24/21 Notable companies reporting before tomorrow's open 02/24/21 Notable companies reporting before tomorrow's open 17 Mar ROKU NLSN ROKU Roku $389.13 / -31.09 (-7.40%) 02/16/21 Streaming device maker Roku is hiring to make original content, Protocol says 02/11/21 ViacomCBS working on '60 Minutes' spinoff for Paramount+, Bloomberg says 01/04/21 Roku in advanced talks to buy Quibi's content catalog, WSJ reports 12/02/20 Roku hires Apple's chief Siri architect Brian Pinkerton, Bloomberg reports NLSN Nielsen $24.83 / +1.74 (+7.54%) 10/27/20 Nielsen in talks with PE group about $2.9B sale of consumer goods unit, FT says ROKU NLSN ROKU Roku $389.13 / -31.09 (-7.40%) 03/01/21 Fly Intel: After-Hours Movers 02/19/21 Fly Intel: Wall Street's top stories for Friday 02/19/21 Fly Intel: Wall Street's top stories at midday 02/19/21 Fly Intel: Pre-market Movers NLSN Nielsen $24.83 / +1.74 (+7.54%) 03/01/21 Fly Intel: After-Hours Movers 11/02/20 Fly Intel: Wall Street's top stories for Monday 11/02/20 Fly Intel: Wall Street's top stories at midday 11/02/20 Fly Intel: Pre-market Movers ROKU NLSN ROKU Roku $389.13 / -31.09 (-7.40%) 02/18/21 Roku options imply 13.2% move in share price post-earnings 01/07/21 Roku call volume above normal and directionally bullish 10/09/20 Unusual call flow in option market yesterday 10/08/20 Roku leads single-stock options after open as shares jump on upgrade NLSN Nielsen $24.83 / +1.74 (+7.54%) 03/02/21 Early notable gainers among liquid option names on March 2nd 12/04/20 Unusual call flow in option market yesterday 12/03/20 Bulls tune in to calls on Nielson Holdings 11/02/20 Early notable gainers among liquid option names on November 2nd
Recommendations	Stratasys price target raised to $34 from $14 at Loop Capital » 07:17 03/03/21 03/03 07:17 03/03/21 07:17 SSYS Stratasys $32.27 / -4.12 (-11.32%) Loop Capital analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Options SSYS Stratasys $32.27 / -4.12 (-11.32%) 03/01/21 Stratasys expects Q1 revenue to track similarly to 1Q20 02/18/21 Stratasys acquires U.K.-based RP Support Ltd., terms not stated 02/18/21 Stratasys acquires RPS, provider of best-in-class' stereolithography 3D printers 12/09/20 Stratasys to acquire Origin for total consideration of up to $100M SSYS Stratasys $32.27 / -4.12 (-11.32%) 01/19/21 Stifel Stratasys initiated with a Buy at Stifel 01/15/21 JPMorgan Stratasys downgraded to Underweight from Neutral at JPMorgan 10/09/20 Berenberg Stratasys initiated with a Buy at Berenberg 09/24/20 Fly Intel: Top five analyst downgrades SSYS Stratasys $32.27 / -4.12 (-11.32%) 03/01/21 Stratasys reports Q4 EPS 13c, consensus 0c 11/12/20 Stratasys reports Q3 non-GAAP EPS (5c), consensus (7c) 03 Mar SSYS Stratasys $32.27 / -4.12 (-11.32%) 03/02/21 Fly Intel: After-Hours Movers 03/01/21 Fly Intel: Pre-market Movers SSYS Stratasys $32.27 / -4.12 (-11.32%) 02/25/21 Stratasys call volume above normal and directionally bullish 01/07/21 Stratasys call volume above normal and directionally bullish 12/17/20 Stratasys call volume above normal and directionally bullish

Hot Stocks	Qiwi CFO Pavel Korzh resigns » 07:17 03/03/21 03/03 07:17 03/03/21 07:17 QIWI Qiwi $11.11 / +0.12 (+1.09%) QIWI announced that Pavel… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Options QIWI Qiwi $11.11 / +0.12 (+1.09%) 12/10/20 Qiwi sinks after Central Bank of Russia puts restrictions on Qiwi Bank 11/19/20 Qiwi appoints Pavel Korzh as CFO QIWI Qiwi $11.11 / +0.12 (+1.09%) 12/11/20 Goldman Sachs Qiwi downgraded to Neutral from Buy at Goldman Sachs 12/10/20 William Blair Qiwi government audit to bring business changes, says William Blair 12/09/20 JPMorgan Qiwi downgraded to Underweight from Neutral at JPMorgan 11/23/20 Qiwi downgraded to Sell from Buy at Sberbank CIB QIWI Qiwi $11.11 / +0.12 (+1.09%) 11/19/20 Qiwi reports Q3 EPS 61c, consensus 60c 22 Jul QIWI Qiwi $11.11 / +0.12 (+1.09%) 12/10/20 Fly Intel: Wall Street's top stories for Thursday 12/10/20 Fly Intel: Wall Street's top stories at midday QIWI Qiwi $11.11 / +0.12 (+1.09%) 03/01/21 Largest borrow rate increases among liquid names
Recommendations	TTEC Holdings price target raised to $110 from $90 at Canaccord » 07:16 03/03/21 03/03 07:16 03/03/21 07:16 TTEC TTEC Holdings $86.51 / -2.22 (-2.50%) Canaccord analyst Joseph… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly TTEC TTEC Holdings $86.51 / -2.22 (-2.50%) 03/01/21 TTEC Holdings raises semi-annual dividend by 7.5% to 43c per share 01/21/21 TTEC Holdings partners with Schwan's Home Delivery 12/03/20 TTEC Holdings declares special, one-time cash dividend of $2.14 per share 09/28/20 TTEC Holdings increases semi-annual cash dividend to 40c per share TTEC TTEC Holdings $86.51 / -2.22 (-2.50%) 12/17/20 Canaccord TTEC Holdings price target raised to $90 from $77 at Canaccord 10/15/20 Canaccord TTEC Holdings model steadily shifts to digital, Canaccord starts with a Buy 10/15/20 Canaccord TTEC Holdings initiated with a Buy at Canaccord 08/10/20 Fly Intel: Top five analyst downgrades TTEC TTEC Holdings $86.51 / -2.22 (-2.50%) 03/01/21 TTEC Holdings sees FY21 EPS $4.06-$4.25, consensus $2.96 03/01/21 TTEC Holdings reports Q4 EPS $1.22, consensus 71c 11/04/20 TTEC Holdings raises FY20 EPS view to $2.92-$3.02 from $2.37-$2.43 11/04/20 TTEC Holdings reports Q3 adjusted EPS 90c, consensus 54c TTEC TTEC Holdings $86.51 / -2.22 (-2.50%) 03/01/21 Fly Intel: After-Hours Movers
Hot Stocks	Greenlane acquires Eyce, terms not disclosed » 07:16 03/03/21 03/03 07:16 03/03/21 07:16 GNLN Greenlane $5.74 / +0.03 (+0.53%) Greenlane Holdings… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research On The Fly Options GNLN Greenlane $5.74 / +0.03 (+0.53%) 02/09/21 Greenlane announces dismissal of remaining securities class action 02/02/21 Greenlane adds three Higher Standard shop locations in Uruguay 01/11/21 Greenlane announces dismissal of class action suit with Prejudice 01/06/21 Greenlane partners with Last Prisoner Project to aid in justice reform GNLN Greenlane $5.74 / +0.03 (+0.53%) 03/31/20 Roth Capital Greenlane price target lowered to $4 from $9 at Roth Capital GNLN Greenlane $5.74 / +0.03 (+0.53%) 12/10/20 Rising High: Canopy Growth shutters Canadian operations, Medmen reports earnings 12/03/20 Rising High: An exclusive talk with distributor Greenlane Holdings GNLN Greenlane $5.74 / +0.03 (+0.53%) 02/09/21 Five new option listings and two option delistings on February 9th
Hot Stocks	Atlas Technical Consultants to acquire Atlantic Engineering Laboratories » 07:15 03/03/21 03/03 07:15 03/03/21 07:15 ATCX Atlas Technical Consultants $9.20 / -0.3 (-3.16%) Atlas Technical… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Syndicate Events ATCX Atlas Technical Consultants $9.20 / -0.3 (-3.16%) 02/26/21 Atlas Technical Consultants announces recapitalization of capital structure 02/02/21 Atlas Technical Consultants announces two management team appointments 01/19/21 Atlas Vista awarded $9M contract from Caltrans 01/12/21 Atlas Technical Consultants awarded $5M contract for OVT&I services ATCX Atlas Technical Consultants $9.20 / -0.3 (-3.16%) 01/08/21 Fly Intel: Top five analyst initiations 01/08/21 Stifel Atlas Technical Consultants initiated with a Buy at Stifel 08/11/20 DA Davidson Atlas Technical Consultants upgraded to Buy from Neutral at DA Davidson 08/11/20 DA Davidson Atlas Technical Consultants upgraded to Buy from Neutral at DA Davidson 14 Aug 03/08/21 Atlas Technical Consultants - ATCX
Recommendations	Kala recent selloff brings attractive entry point, says JPMorgan » 07:15 03/03/21 03/03 07:15 03/03/21 07:15 KALA Kala Pharmaceuticals / + JPMorgan analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events KALA Kala Pharmaceuticals / + 02/16/21 Kala Pharmaceuticals announces Eysuvis added to Express Scripts formularies 01/07/21 Kala Pharmaceuticals launches Eysuvis for dry eye disease 11/16/20 Kala Pharmaceuticals provides update on Eysuvis launch plans 10/27/20 Kala Pharmaceuticals receives FDA approval for Eysuvis KALA Kala Pharmaceuticals / + 10/28/20 Wedbush Kala Pharmaceuticals price target raised to $47 from $39 at Wedbush 09/14/20 Fly Intel: Top five analyst downgrades 09/14/20 Jefferies Jefferies downgrades Kala to Hold, cuts target to $10 following physician survey 09/14/20 Jefferies Kala Pharmaceuticals downgraded to Hold from Buy at Jefferies KALA Kala Pharmaceuticals / + 02/25/21 Kala Pharmaceuticals reports Q4 EPS (55c), consensus (46c) 11/05/20 Kala Pharmaceuticals reports Q3 EPS (50c), consensus (44c) 11 Mar KALA Kala Pharmaceuticals / + 09/14/20 Fly Intel: Wall Street's top stories for Monday 09/14/20 Fly Intel: Wall Street's top stories at midday 09/14/20 GameStop upgrades, MGM downgrade among today's top calls on Wall Street 03/16/21 31st Annual Healthcare Virtual Conference

Recommendations	Sea Limited price target raised to $260 from $225 at Stifel » 07:15 03/03/21 03/03 07:15 03/03/21 07:15 SE Sea Limited $250.44 / +1.635 (+0.66%) Stifel analyst Scott… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Options SE Sea Limited $250.44 / +1.635 (+0.66%) 03/02/21 Sea Limited sees FY21 bookings for digital entertainment $4.3B-$4.5B 12/04/20 Sea Limited awarded license to operate digital full bank in Singapore 11/17/20 Sea Limited sees FY20 bookings for digital entertainment up 75.4% from last year SE Sea Limited $250.44 / +1.635 (+0.66%) 02/23/21 Cowen Sea Limited price target raised to $320 from $225 at Cowen 02/01/21 China Renaissance Sea Limited initiated with a Buy at China Renaissance 02/01/21 Morgan Stanley Sea Limited price target raised to $250 from $188 at Morgan Stanley 01/08/21 Stifel Sea Group secures banking license in Indonesia, says Stifel SE Sea Limited $250.44 / +1.635 (+0.66%) 03/02/21 Sea Limited reports Q4 EPS (87c) ex-items, consensus (54c) 02/16/21 Tiger Global bought DoorDash and 1Life during Q4, sold out of Alphabet 11/17/20 Sea Limited reports Q3 EPS (38c), consensus (53c) 11 Dec SE Sea Limited $250.44 / +1.635 (+0.66%) 01/14/21 Sea acquired majority control of Indonesian lender, Nikkei reports 12/10/20 Sea Limited to upsize deal by 20% to $2.57B priced at $195 per share, IFR says SE Sea Limited $250.44 / +1.635 (+0.66%) 11/17/20 Fly Intel: Pre-market Movers SE Sea Limited $250.44 / +1.635 (+0.66%) 03/02/21 Unusually active option classes on open March 2nd 02/01/21 Sea Limited call volume above normal and directionally bullish 01/28/21 Sea Limited call volume above normal and directionally bullish 01/08/21 Sea Limited call volume above normal and directionally bullish
Hot Stocks	Zoom Video rises after one of Cathie Wood's ARK ETFs discloses holdings » 07:15 03/03/21 03/03 07:15 03/03/21 07:15 ZM Zoom Video $372.72 / -36.95 (-9.02%) Shares of Zoom Video (ZM)… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Options ZM Zoom Video $372.72 / -36.95 (-9.02%) 03/01/21 Zoom Video jumps 8% to $444.10 after Q4 results, FY22 guidance beat estimates 03/01/21 Lumen announces launch of Zoom Phone 02/03/21 Zoom Video announces availability of Zoom Rooms innovations 01/26/21 User reports indicate Zoom Video experiencing issues, says DownDetector ZM Zoom Video $372.72 / -36.95 (-9.02%) 03/02/21 Fly Intel: Top five analyst upgrades 03/02/21 Morgan Stanley Zoom Video price target raised to $420 from $390 at Morgan Stanley 03/02/21 Piper Sandler Zoom Video upgraded to Overweight from Neutral at Piper Sandler 01/26/21 MKM Partners Fiverr downgraded to Sell from Neutral at MKM Partners ZM Zoom Video $372.72 / -36.95 (-9.02%) 03/01/21 Zoom Video sees FY22 EPS $3.59-$3.65, consensus $2.96 03/01/21 Zoom Video sees Q1 EPS 95c-97c, consensus 72c 03/01/21 Zoom Video reports Q4 EPS $1.22, consensus 79c 03/01/21 Notable companies reporting after market close 13 Jan ZM Zoom Video $372.72 / -36.95 (-9.02%) 12/23/20 Zoom Video developing web email service, Information reports 11/13/20 NYC mayor warns parents to plan for school shutdown, Bloomberg reports 11/10/20 Microsoft wants to demolish video-conferencing competition, BI reports 10/14/20 Zoom's Yuan says won't develop chat service to rival Slack, Bloomberg reports ZM Zoom Video $372.72 / -36.95 (-9.02%) 03/02/21 Fly Intel: Wall Street's top stories for Tuesday 03/02/21 Piper Sandler upgrades Zoom Video after 'very strong end' to FY21 03/02/21 Fly Intel: Wall Street's top stories at midday 03/02/21 Zoom Video, TripAdvisor upgrades among today's top calls ZM Zoom Video $372.72 / -36.95 (-9.02%) 03/01/21 Zoom Video Communications options imply 15.8% move in share price post-earnings 02/05/21 Zoom Video Communications call volume above normal and directionally bullish 01/15/21 Zoom Video Communications call volume above normal and directionally bullish 01/12/21 Zoom Video Communications call volume above normal and directionally bullish
Hot Stocks	Actinium Pharmaceuticals appoints Mark Kubik as Chief Business Office » 07:15 03/03/21 03/03 07:15 03/03/21 07:15 ATNM Actinium Pharmaceuticals $8.15 / +0.1 (+1.24%) Actinium Pharmaceuticals… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Syndicate On The Fly ATNM Actinium Pharmaceuticals $8.15 / +0.1 (+1.24%) 01/13/21 Actinium, Astellas Pharma announce research pact focused on radiotherapies 12/29/20 Actinium says DMC recommends Phase 3 SIERRA trial 'continue as planned' 12/08/20 Actinium reports 67% ORR in first cohort in Actimab-A venetoclax combination 12/07/20 Actinium Pharmaceuticals announces 'positive' results from Phase 3 SIERRA trial ATNM Actinium Pharmaceuticals $8.15 / +0.1 (+1.24%) 12/29/20 H.C. Wainwright H.C. Wainwright keeps Buy on Actinium amid 'headline disappointment' 12/29/20 JonesTrading Actinium selloff today 'clear buying opportunity,' says JonesTrading 11/05/20 Fly Intel: Top five analyst initiations 11/05/20 Alliance Global Partners Actinium Pharmaceuticals initiated with a Buy at Alliance Global Partners 17 Jun 22 Apr ATNM Actinium Pharmaceuticals $8.15 / +0.1 (+1.24%) 12/29/20 Fly Intel: Wall Street's top stories for Tuesday 12/29/20 Fly Intel: Wall Street's top stories at midday
Recommendations	TransMedics price target raised to $46 from $20 at Canaccord » 07:14 03/03/21 03/03 07:14 03/03/21 07:14 TMDX TransMedics $39.55 / +3.305 (+9.12%) Canaccord analyst Cecilia… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events TMDX TransMedics $39.55 / +3.305 (+9.12%) 03/01/21 TransMedics announces scheduling of OCS Heart FDA AdCom meeting 09/28/20 FDA postpones advisory committee meeting to review TransMedics OCS Heart TMDX TransMedics $39.55 / +3.305 (+9.12%) 03/02/21 Oppenheimer TransMedics price target raised to $40 from $25 at Oppenheimer 02/24/21 Cowen TransMedics price target raised to $44 from $20 at Cowen 10/08/20 Fly Intel: Top five analyst downgrades 10/08/20 JPMorgan TransMedics downgraded to Neutral on 'missed' execution at JPMorgan TMDX TransMedics $39.55 / +3.305 (+9.12%) 03/02/21 TransMedics reports Q4 EPS (23c), consensus (25c) 11/04/20 TransMedics reports Q3 EPS (19c), consensus (32c). 27 May TMDX TransMedics $39.55 / +3.305 (+9.12%) 03/01/21 Fly Intel: After-Hours Movers 03/02/21 41st Annual Healthcare Virtual Conference
Hot Stocks	BioXcel schedules End of Phase 2 meeting for BXCL501 in 2Q21 » 07:14 03/03/21 03/03 07:14 03/03/21 07:14 BTAI BioXcel Therapeutics $52.76 / -2.735 (-4.93%) BioXcel Therapeutics… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly BTAI BioXcel Therapeutics $52.76 / -2.735 (-4.93%) 03/01/21 BioXcel Therapeutics appoints June Bray to board of directors 02/25/21 BioXcel Therapeutics announces initiation of Phase 2 Placidity trial of BXCL501 02/23/21 BioXcel Therapeutics names Javier Rodriguez as chief legal officer 02/12/21 BioXcel Therapeutics to host KOL event to highlight BXCL501 BTAI BioXcel Therapeutics $52.76 / -2.735 (-4.93%) 02/01/21 UBS BioXcel Therapeutics initiated with a Buy at UBS 01/06/21 H.C. Wainwright BioXcel Therapeutics price target raised to $185 from $175 at H.C. Wainwright 10/30/20 Fly Intel: Top five analyst initiations 10/30/20 Goldman Sachs BioXcel Therapeutics initiated with a Buy at Goldman Sachs BTAI BioXcel Therapeutics $52.76 / -2.735 (-4.93%) 11/12/20 BioXcel Therapeutics reports Q3 EPS ($1.07), consensus (80c) 29 Jul BTAI BioXcel Therapeutics $52.76 / -2.735 (-4.93%) 01/05/21 Fly Intel: Pre-market Movers

Recommendations	Ambarella price target raised to $135 from $128 at Stifel » 07:12 03/03/21 03/03 07:12 03/03/21 07:12 AMBA Ambarella / + Stifel analyst Tore… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options AMBA Ambarella / + 03/02/21 Ambarella jumps 7% to $121.95 after Q4 results top estimates 03/02/21 Motional selects Ambarella CVflow AI processors for driverless vehicles 01/11/21 Ambarella unveils CV5 AI vision processor with 8K capabilities 12/28/20 FAA adopts final rules for drones 'advancing opportunities' for utilization AMBA Ambarella / + 02/24/21 Deutsche Bank Ambarella price target raised to $100 from $75 at Deutsche Bank 01/21/21 Stifel Ambarella price target raised to $118 from $110 at Stifel 01/13/21 Roth Capital Ambarella upgraded to Buy with $130 price target at Roth Capital 01/13/21 Roth Capital Ambarella upgraded to Buy from Neutral at Roth Capital AMBA Ambarella / + 03/02/21 Ambarella reports Q4 EPS 14c, consensus 8c 11/24/20 Ambarella sees Q4 revenue $56M-$60M, consensus $52.31M 11/23/20 Ambarella reports Q3 EPS 9c, consensus 5c AMBA Ambarella / + 03/02/21 Fly Intel: After-Hours Movers 12/14/20 Fly Insider: Molecular Templates, AMD among notable insider trades 12/07/20 Fly Insider: Foot Locker, Alexion among weeks notable insider trades 11/23/20 Fly Intel: After-Hours Movers 03/15/21 33rd Annual Roth Virtual Conference AMBA Ambarella / + 02/01/21 Ambarella call volume above normal and directionally bullish 01/21/21 Ambarella call volume above normal and directionally bullish 12/10/20 Ambarella call volume above normal and directionally bullish 12/03/20 Ambarella call volume above normal and directionally bullish
Recommendations	Quanterix price target raised to $90 from $86 at Canaccord » 07:12 03/03/21 03/03 07:12 03/03/21 07:12 QTRX Quanterix $77.06 / -5.61 (-6.79%) Canaccord analyst Max… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events Options QTRX Quanterix $77.06 / -5.61 (-6.79%) 02/12/21 Quanterix announces Simoa joint laboratory with WuXi AppTec 01/11/21 Quanterix gets FDA emergency use authorization for COVID protein antigen test 12/28/20 Quanterix gets FDA EUA for COVID antibody test with Simoa 12/24/20 Quanterix gets EUA for Simoa Semi-Quantitative SARS-CoV-2 IgG Antibody Test QTRX Quanterix $77.06 / -5.61 (-6.79%) 01/27/21 SVB Leerink Quanterix price target raised to $75 from $50 at SVB Leerink 01/14/21 Canaccord Quanterix price target raised to $74 from $60 at Canaccord 01/12/21 Canaccord Quanterix price target raised to $60 from $54 at Canaccord 10/19/20 SVB Leerink Quanterix price target raised to $48 from $37 at SVB Leerink QTRX Quanterix $77.06 / -5.61 (-6.79%) 03/02/21 Quanterix reports Q4 loss from operations ($11.7M) vs. ($10.8M) last year 04 Feb 07 Aug QTRX Quanterix $77.06 / -5.61 (-6.79%) 03/02/21 Fly Intel: After-Hours Movers 01/11/21 Fly Intel: After-Hours Movers 03/02/21 41st Annual Healthcare Virtual Conference QTRX Quanterix $77.06 / -5.61 (-6.79%) 10/21/20 Eleven new option listings and one option delisting on October 21st
Hot Stocks	Charlotte's Web to enter U.S. cannabis wellness market » 07:12 03/03/21 03/03 07:12 03/03/21 07:12 CWBHF Charlotte's Web $0.00 / + (+0.00%) Charlotte's Web… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research On The Fly Events CWBHF Charlotte's Web $0.00 / + (+0.00%) 02/26/21 Charlotte's Web announces scientific collaboration with McLean Hospital 01/12/21 Charlotte's Web announces two U.S. utility patents for hemp genetics CWBHF Charlotte's Web $0.00 / + (+0.00%) 09/15/20 Piper Sandler Charlotte's Web price target lowered to $4 from $7 at Piper Sandler 06/12/20 Cowen Charlotte's Web initiated with an Outperform at Cowen 03/23/20 Canaccord Charlotte's Web price target lowered to C$10 from C$17 at Canaccord 03/09/20 Cantor Fitzgerald Charlotte's Web price target lowered to $7 from $11.70 at Cantor Fitzgerald CWBHF Charlotte's Web $0.00 / + (+0.00%) 11/12/20 Rising High: Cannabis companies report earnings 03/25/21 Charlotte's Web - CWBHF
Downgrade	Singapore Airlines downgraded to Neutral from Overweight at JPMorgan » 07:12 03/03/21 03/03 07:12 03/03/21 07:12 SINGY Singapore Airlines $0.00 / + (+0.00%) JPMorgan analyst Karen Li… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research SINGY Singapore Airlines $0.00 / + (+0.00%) 12/15/20 DBS Bank Singapore Airlines downgraded to Fully Valued from Hold at DBS Bank 11/10/20 JPMorgan Singapore Airlines upgraded to Overweight from Underweight at JPMorgan 11/09/20 Goldman Sachs Singapore Airlines upgraded to Neutral from Sell at Goldman Sachs 07/30/20 CIMB Singapore Airlines downgraded to Hold from Add at CIMB
Hot Stocks	Passage Bio announces anticipated upcoming milestones » 07:12 03/03/21 03/03 07:12 03/03/21 07:12 PASG Passage Bio $19.58 / + (+0.00%) Anticipated Upcoming… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events Options PASG Passage Bio $19.58 / + (+0.00%) 02/19/21 Passage Bio appoints Maxine Gowen to board of directors 02/08/21 Passage Bio's IND application for Krabbe disease candidate cleared by FDA 01/28/21 Passage Bio annoounces FDA IND clearance for PBFT02 01/11/21 Passage Bio says PBGM01 entering clinic to study safety, efficacy PASG Passage Bio $19.58 / + (+0.00%) 02/04/21 Fly Intel: Top five analyst initiations 02/04/21 Guggenheim Passage Bio initiated with a Buy at Guggenheim 01/25/21 Citi Citi upgrades Passage Bio to Buy after pullback and ahead of data 01/25/21 Citi Passage Bio upgraded to Buy from Neutral at Citi PASG Passage Bio $19.58 / + (+0.00%) 07:11 Today Passage Bio reports Q4 EPS (85c), consensus (70c) 11/10/20 Passage Bio reports Q3 EPS (63c), consensus (76c) 22 Jan PASG Passage Bio $19.58 / + (+0.00%) 01/22/21 Fly Intel: Wall Street's top stories for Friday 01/22/21 Fly Intel: Wall Street's top stories at midday 08:30 Today Passage Bio - PASG PASG Passage Bio $19.58 / + (+0.00%) 12/09/20 Nine new option listings on December 9th

Hot Stocks	Marker Therapeutics doses first patient in Phase 2 trial of MT-401 in AML » 07:12 03/03/21 03/03 07:12 03/03/21 07:12 MRKR Marker Therapeutics $2.50 / -0.04 (-1.57%) Marker Therapeutics has… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events MRKR Marker Therapeutics $2.50 / -0.04 (-1.57%) 01/05/21 Marker Therapeutics trading resumes 01/05/21 Marker Therapeutics: FDA lifts partial clinical hold on Phase 2 trial of MT-401 01/05/21 Marker Therapeutics trading halted, news pending MRKR Marker Therapeutics $2.50 / -0.04 (-1.57%) 01/05/21 Oppenheimer Marker hits 'important milestone' with end of clinical hold, says Oppenheimer 05/12/20 Fly Intel: Top five analyst downgrades 05/12/20 Piper Sandler Marker Therapeutics downgraded to Neutral from Overweight at Piper Sandler MRKR Marker Therapeutics $2.50 / -0.04 (-1.57%) 11/09/20 Marker Therapeutics reports Q3 EPS (16c), consensus (14c) 03/16/21 31st Annual Healthcare Virtual Conference
Earnings	Passage Bio reports Q4 EPS (85c), consensus (70c) » 07:11 03/03/21 03/03 07:11 03/03/21 07:11 PASG Passage Bio $19.58 / + (+0.00%) "At Passage Bio, we… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events Options PASG Passage Bio $19.58 / + (+0.00%) 02/19/21 Passage Bio appoints Maxine Gowen to board of directors 02/08/21 Passage Bio's IND application for Krabbe disease candidate cleared by FDA 01/28/21 Passage Bio annoounces FDA IND clearance for PBFT02 01/11/21 Passage Bio says PBGM01 entering clinic to study safety, efficacy PASG Passage Bio $19.58 / + (+0.00%) 02/04/21 Fly Intel: Top five analyst initiations 02/04/21 Guggenheim Passage Bio initiated with a Buy at Guggenheim 01/25/21 Citi Citi upgrades Passage Bio to Buy after pullback and ahead of data 01/25/21 Citi Passage Bio upgraded to Buy from Neutral at Citi PASG Passage Bio $19.58 / + (+0.00%) 11/10/20 Passage Bio reports Q3 EPS (63c), consensus (76c) 22 Jan PASG Passage Bio $19.58 / + (+0.00%) 01/22/21 Fly Intel: Wall Street's top stories for Friday 01/22/21 Fly Intel: Wall Street's top stories at midday 08:30 Today Passage Bio - PASG PASG Passage Bio $19.58 / + (+0.00%) 12/09/20 Nine new option listings on December 9th
Recommendations	Pulmonx price target raised to $65 from $49 at Canaccord » 07:11 03/03/21 03/03 07:11 03/03/21 07:11 LUNG Pulmonx $57.93 / -2.37 (-3.93%) Canaccord analyst William… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Options LUNG Pulmonx $57.93 / -2.37 (-3.93%) 12/08/20 Pulmonx appoints Georgia Garinois-Melenikiotou, Thomas Burns to board 11/30/20 Pulmonx announces over 20,000 patient treated with non-surgical Zephyr Valve LUNG Pulmonx $57.93 / -2.37 (-3.93%) 01/04/21 BofA Pulmonx downgraded to Neutral from Buy at BofA 10/26/20 BofA Pulmonx initiated with a Buy at BofA 10/26/20 Canaccord Pulmonx initiated with a Buy at Canaccord 10/26/20 Morgan Stanley Pulmonx initiated with an Equal Weight at Morgan Stanley LUNG Pulmonx $57.93 / -2.37 (-3.93%) 03/02/21 Pulmonx reports Q4 EPS (27c), consensus (28c) 01 Oct LUNG Pulmonx $57.93 / -2.37 (-3.93%) 10/04/20 Opening Day: Palantir, Asana go public via direct listings LUNG Pulmonx $57.93 / -2.37 (-3.93%) 02/04/21 Six new option listings and one option delisting on February 4th
Earnings	Taysha Gene Therapies reports Q4 EPS (12c), consensus (37c) » 07:10 03/03/21 03/03 07:10 03/03/21 07:10 TSHA Taysha Gene Therapies $25.78 / -0.99 (-3.70%) Cash and cash… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Syndicate On The Fly Events TSHA Taysha Gene Therapies $25.78 / -0.99 (-3.70%) 02/09/21 Taysha Gene Therapies announces multi-year collaborations for AAV gene therapies 01/26/21 Taysha Gene Therapies appoints Timothy Douros as CLO, Tracy Porter as CPO 01/19/21 Taysha gets both rare pediatric disease and orphan drug designations for TSHA-10 01/04/21 Taysha Gene Therapies announces multi-year collaboration with AllStripes TSHA Taysha Gene Therapies $25.78 / -0.99 (-3.70%) 02/23/21 William Blair William Blair starts Taysha with Outperform, $46 fair-value estimate 02/23/21 William Blair William Blair starts Taysha Gene Therapies with Outperform on positive FDA draft 02/23/21 William Blair Taysha Gene Therapies initiated with an Outperform at William Blair 01/04/21 Oppenheimer Taysha Gene Therapies initiated with an Outperform at Oppenheimer 24 Sep TSHA Taysha Gene Therapies $25.78 / -0.99 (-3.70%) 09/27/20 Opening Day: GoodRx rises over 50% in market debut 09/20/20 Opening Day: Snowflake shares double in biggest software IPO ever 03/16/21 31st Annual Healthcare Virtual Conference 08:00 Today Taysha Gene Therapies - TSHA
Hot Stocks	Carrols Restaurant targets 2021 net capital expenditures approx. $60M » 07:10 03/03/21 03/03 07:10 03/03/21 07:10 TAST Carrols Restaurant $6.55 / +0.16 (+2.50%) Daniel T. Accordino,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events TAST Carrols Restaurant $6.55 / +0.16 (+2.50%) 02/10/21 Carrols Restaurant appoints Jared Landaw as VP, general counsel 02/09/21 Carrols Restaurant appoints Carl Hauch as COO TAST Carrols Restaurant $6.55 / +0.16 (+2.50%) 01/15/21 BMO Capital Restaurant Brands price target raised to $70 from $65 at BMO Capital 01/15/21 Deutsche Bank Carrols Restaurant price target raised to $8 from $7 at Deutsche Bank 01/12/21 Baird Baird cautious Restaurant Brands ahead of results 11/09/20 Deutsche Bank Carrols Restaurant price target lowered to $7 from $8 at Deutsche Bank TAST Carrols Restaurant $6.55 / +0.16 (+2.50%) 07:08 Today Carrols Restaurant reports Q4 adjusted EPS 0c, consensus 2c 01/11/21 Carrols Restaurant sees 2020 revenue $1.55B, consensus $1.55B 01/11/21 Carrols Restaurant sees Q4 revenue $420.5M, consensus $421.47M 11/05/20 Carrols Restaurant reports Q3 EPS 9c, consensus 11c 08:30 Today Carrols Restaurant - TAST 03/26/21 Carrols Restaurant

Events

Earnings calls, analyst events, roadshows and more

BQ
Today at 08:00

Boqii - BQ Conference Calls
ISEE
Today at 08:00

Iveric bio - ISEE Conference Calls
TSHA
Today at 08:00

Taysha Gene Therapies - TSHA Conference Calls
OPTN
Today at 08:00

Optinose - OPTN Conference Calls
Today at 08:15

ADP Employment Report: Private Payrolls M/M: February 2021 Government Event
CECE
Today at 08:30

CECO Environmental - CECE Conference Calls
SBBP
Today at 08:30

Strongbridge Biopharma - SBBP Conference Calls
WEN
Today at 08:30

Wendy's - WEN Conference Calls
TAST
Today at 08:30

Carrols Restaurant - TAST Conference Calls
PASG
Today at 08:30

Passage Bio - PASG Conference Calls

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	SWTX X SWTX SpringsWorks Therapeutics Block Trade Managers: Morgan Stanley Priced at: $84.00 1.2M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial VRT X VRT Vertiv Holdings Block Trade Managers: JPMorgan Priced at: $20.70 17.4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial KRTX X KRTX Karuna Therapeutics Secondary Managers: Goldman Sachs & JPMorgan Priced at: $120.00 2.08M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SYNH X SYNH Syneos Health Secondary Managers: Goldman Sachs Priced at: $74.95 7M Shares EAF X EAF GrafTech Spot Secondary Managers: Morgan Stanley Priced at: $11.88 30M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial FRC X FRC First Republic Spot Secondary Managers: BofA, JPMorgan & Morgan Stanley Priced at: $166.50 1.75M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial HLNE X HLNE Hamilton Lane Spot Secondary Managers: JPMorgan Priced at: $88.25 1.45M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial JELD X JELD Jeld-Wen Spot Secondary Managers: Goldman Sachs Priced at: $29.25 8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial RCL X RCL Royal Caribbean Spot Secondary Managers: Morgan Stanley Priced at: $91.00 16.938M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SITC X SITC Site Centers Spot Secondary Managers: Morgan Stanley & Wells Fargo Priced at: $13.20 15M Shares WSC X WSC WillScot Mobile Mini Spot Secondary Managers: Morgan Stanley Priced at: $27.20 12.75M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Tues	OSCR X OSCR Oscar Health IPO Managers: Goldman Sachs, Morgan Stanley & Allen & Co., Wells Fargo, Credit Suisse, BofA, Cowen, LION, Ramirez, SIEB Priced at: $39.00 31M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ASLN X ASLN Aslan Pharmaceuticals Secondary Managers: Jefferies & Piper Sandler Priced at: $4.00 15M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CDLX X CDLX Cardlytics Secondary Managers: BofA, JPMorgan, Wells Fargo & Raymond James Priced at: $130.00 3.85M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial HSKA X HSKA Heska Secondary Managers: JPMorgan & Piper Sandler Priced at: $186.00 941K Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial INDT X INDT Indus Realty Trust Secondary Managers: Morgan Stanley, Citi & Baird, BTIG, JMP Securities, JPMorgan Priced at: $60.00 1.75M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MORF X MORF Morphic Secondary Managers: Jefferies, Cowen, BMO Capital & RBC Capital Priced at: $70.00 3.5M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ICAD X ICAD iCAD Spot Secondary Managers: Guggenheim Priced at: $18.00 1.222M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MGY X MGY Magnolia Oil & Gas Spot Secondary Managers: Credit Suisse & Citi Priced at: $10.50 17M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ORC X ORC Orchid Island Capital Spot Secondary Managers: JPMorgan Priced at: $5.55 8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial RDHL X RDHL RedHill Biopharma Spot Secondary Managers: H.C. Wainwright Priced at: $8.00 4.375M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SSYS X SSYS Stratasys Spot Secondary Managers: JPMorgan & Stifel Priced at: $29.00 6.897M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	No deals
Thurs	No deals
Fri	No deals

Mon	No deals
Tues	GROY X GROY Gold Royalty IPO Managers: H.C. Wainwright & BMO Capital, CIBC, HAYW, Raymond James, Roth Capital, Scotiabank, Sprott, TD Securities $5.00 16M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial PLXP X PLXP PLx Pharma Spot Secondary Managers: Raymond James & Oppenheimer $9.14 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	INNV X INNV InnovAge IPO Managers: JPMorgan, Barclays, Goldman Sachs & Citi, Baird, William Blair, Piper Sandler, Capital One, Loop Capital, SIEB, Roberts & Ryans $17.00-19.00 16.667M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial AMRK X AMRK A-Mark Precious Metals Secondary Managers: DA Davidson & Roth Capital, CIBC $27.97 2.5M Shares COHU X COHU Cohu Secondary Managers: Citi, Goldman Sachs & Stifel, B. Riley Securities, Craig-Hallum, DA Davidson $45.99 4.5M Shares DGII X DGII Digi International Secondary Managers: Piper Sandler $23.46 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial FVRR X FVRR Fiverr Secondary Managers: JPMorgan, Goldman Sachs, Morgan Stanley $279.44 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SLQT X SLQT SelectQuote Secondary Managers: Credit Suisse, Morgan Stanley, Goldman Sachs, RBC Capital, Barclays, Citi, Evercore ISI & Jefferies, Cantor Fitzgerald, Keefe Bruyette, Piper Sandler, Drexel Hamilton $32.22 10.6M Shares
Thurs	NRIX X NRIX Nurix Therapeutics Secondary Managers: JPMorgan, Piper Sandler & Stifel, RBC Capital, Needham $35.91 4M Shares
Fri	No deals

View All Syndicate Announcements »

PG&E says on track for court confirmation of plan of reorganization by June 30

TODAY'S FREE FLY STORIES

Get Full Fly Access